<DOC>
	<DOCNO>NCT00003552</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy kill tumor cell . PURPOSE : Phase I/II trial study effectiveness chemotherapy plus peripheral stem cell transplantation treat patient metastatic melanoma .</brief_summary>
	<brief_title>Chemotherapy Peripheral Stem Cell Transplantation Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Identify antitumor effect allogeneic peripheral blood stem cell transplantation ( PBSCT ) patient metastatic melanoma . II . Evaluate safety toxicity nonmyeloablative , low intensity , preparative regimen follow HLA-matched allogeneic PBSCT patient . III . Monitor engraftment measure donor-recipient chimerism lymphoid myeloid lineages patient . IV . Investigate relationship donor-host chimerism incidence acute chronic graft-versus-host disease patient population . V. Investigate effect lymphocyte infusion donor-host chimerism patient population . VI . Determine disease-free survival , overall survival , mortality procedure tumor progression patient population . PROTOCOL OUTLINE : This dose-escalation study condition regimen . Patients receive 1 3 dose level chemotherapy prior peripheral blood progenitor cell ( PBPC ) transplantation . Patients dose level 1 receive cyclophosphamide IV 1 hour day -7 -6 fludarabine IV 30 minute daily day -5 -1 . Patients dose level 2 receive cyclophosphamide IV 1 hour day -7 -6 , fludarabine IV 30 minute daily day -5 -1 , antithymocyte globulin daily day -5 -2 . Patients dose level 3 receive cyclophosphamide IV 1 hour daily day -8 -6 , fludarabine IV 30 minute daily day -5 -1 , antithymocyte globulin daily day -5 -2 . Patients undergo mobilize CD34+ PBPC transplantation day 0 . PBPC transplantation may repeat day 1 2 deem necessary . Patients progressive disease day 15-30 , day 60 , day 100 , without graft-versus-host disease , receive infusion ( ) donor lymphocyte . Further donor lymphocyte infusion day 100 may give discretion attend physician . Patients follow every 2 month 6 month , every 3 month next 2 year , every 6 month year 5 posttransplantation . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Histologically confirm metastatic melanoma amenable complete surgical resection progressive despite immunotherapy and/or chemotherapy Bidimensionally evaluable clinically radiographically HLA 6/6 5/6 match sibling donor available No CNS metastases Prior/Concurrent Therapy See Disease Characteristics At least 30 day since prior treatment melanoma Patient Characteristics Age : 18 60 Performance status : ECOG 01 Life expectancy : At least 3 month Hematopoietic : Not specify Hepatic : Bilirubin great 4 mg/dL Transaminases great 3 time upper limit normal Renal : Creatinine great 2.5 mg/dL Cardiovascular : Left ventricular ejection fraction great 40 % Pulmonary : DLCO great 65 % predict Other : HIV negative No major organ dysfunction preclude transplantation No malignancy except basal cell squamous cell skin cancer No psychiatric disorder mental deficiency would preclude study Not pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>adult solid tumor</keyword>
	<keyword>body system/site cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>skin tumor</keyword>
	<keyword>solid tumor</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>stage , melanoma</keyword>
</DOC>